GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Beta

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Beta : N/A (As of Apr. 28, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-28), Clarus Therapeutics Holdings's Beta is Not available.


Clarus Therapeutics Holdings Beta Historical Data

The historical data trend for Clarus Therapeutics Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Beta Chart

Clarus Therapeutics Holdings Annual Data
Trend Dec20 Dec21
Beta
- -

Clarus Therapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Beta Get a 7-Day Free Trial - - - - -

Competitive Comparison of Clarus Therapeutics Holdings's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarus Therapeutics Holdings's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Beta falls into.



Clarus Therapeutics Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Clarus Therapeutics Holdings  (OTCPK:CRXTQ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Clarus Therapeutics Holdings Beta Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus